A House panel found pharmaceutical companies exponentially increased drug prices to boost profits; CDC data show an increase in alcohol-related deaths, especially among women; 4 million more Americans enroll in Medicaid.
The Democrat-led House Oversight and Reform Committee found major pharmaceutical companies increased drug prices exponentially to boost profits and executives’ bonuses, taking advantage of Medicare rules, Politico reports. The announcement comes after an 18-month investigation into the pricing practices of 12 drug companies, including Bristol Myers Squibb and Teva Pharmaceuticals. The report found Celgene, which was acquired by Bristol in 2019, raised the price of Revlimid, a cancer medication, 22 times since it launched in 2005. The raises ultimately tripled the drug’s price, while reports show in 2014, increases were ordered so the company could meet its quarterly revenue targets.
New CDC data show that alcohol-induced deaths among adults aged 25 and over increased 43% between 2006 and 2018, compared with stable rates seen from 2000 to 2006. Analyses found that between 2000 and 2018, alcohol-induced deaths increased at a greater rate for both males and females residing in rural areas of the country compared with urban areas. Deadly conditions cited by the CDC include those associated with muscle, liver, heart, or brain damage due to alcohol consumption. Since 2000, the number of women dying from these complications has grown by 76%. However, the data does not account for 2020 rates, and more recent analyses show alcohol consumption rose sharply during the pandemic.
Between February and June of 2020, 4 million more Americans enrolled in Medicaid, marking an increase of 5.7%, after a slow decline in enrollment began in mid-2017, CNN reports. The coronavirus disease 2019 (COVID-19) pandemic has caused millions of individuals to lose their jobs and in some cases, their health insurance. Federal data showed over 2.4 million adults enrolled in the program in the Spring of 2020, in addition to 1.4 million children who enrolled in either Medicaid of the Children’s Health Insurance Program. The data includes statistics from all states except Arizona and Washington DC.
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
2 Commerce Drive
Cranbury, NJ 08512